Business Context and Reporting Period
Company: Relmada Therapeutics, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: December 9, 2015
Event: The Company filed a lawsuit in the U.S. District Court for the District of Nevada against Laidlaw & Company (UK) Ltd. and its principals, Matthew Eitner and James Ahern.
Financial Metrics
This filing is a current report regarding a legal event and does not contain financial statements. The filing text does not provide clear values for revenue, profit, cash flow, margins, debt, or liquidity.
Material Changes
The primary material change reported is the initiation of legal proceedings alleging that Laidlaw's December 4, 2015 press release and Schedule 14A filing contained material misrepresentations and omissions in violation of federal securities laws (specifically Rule 14a-9). The Company also alleges conflicts with its Articles of Incorporation, Bylaws, and Nevada law.
Outlook, Risks, and Contingencies
- Legal Action: The Company has filed a motion for a temporary restraining order to enjoin Laidlaw from disseminating false information and soliciting proxies under misleading pretenses.
- Objective: To protect stockholders from misinformation and to compel the correction of previously issued statements.
- Exhibits: The filing includes the press release (Exhibit 99.1), the Complaint (Exhibit 99.2), and the Motion for a Temporary Restraining Order (Exhibit 99.3).
Key Facts for Investor Verification
- Verify the status of the lawsuit and the temporary restraining order motion filed on December 9, 2015.
- Review the specific allegations of misrepresentation in Laidlaw's December 4, 2015 press release and Schedule 14A filing.
- Monitor potential impacts on the Company's proxy solicitation process and shareholder voting.
- Check for subsequent filings regarding the outcome of the legal dispute or any settlement discussions.